Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History RYTM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics RYTM

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Rhythm Pharmaceuticals Inc

RYTM
Current price
89.04 USD -2.76 USD (-3.01%)
Last closed 65.14 USD
ISIN US76243J1051
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 4 184 385 792 USD
Yield for 12 month +91.07 %
1Y
3Y
5Y
10Y
15Y
RYTM
21.11.2021 - 28.11.2021

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts. Address: 222 Berkeley Street, Boston, MA, United States, 02116

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

83.42 USD

P/E Ratio

Dividend Yield

Financials RYTM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures RYTM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+130 126 000 USD

Last Year

+77 428 000 USD

Current Quarter

+32 704 000 USD

Last Quarter

+41 830 000 USD

Current Year

+116 758 000 USD

Last Year

+68 126 000 USD

Current Quarter

+29 056 000 USD

Last Quarter

+38 043 000 USD
EBITDA -263 479 008 USD
Operating Margin TTM -143.73 %
Price to Earnings
Return On Assets TTM -51.33 %
PEG Ratio
Return On Equity TTM -150.20 %
Wall Street Target Price 83.42 USD
Revenue TTM 136 863 008 USD
Book Value 0.30 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 25.90 %
Dividend Yield
Gross Profit TTM 122 654 000 USD
Earnings per share -2.80 USD
Diluted Eps TTM -2.80 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -123.28 %

Stock Valuation RYTM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 29.36
Price Sales TTM 30.57
Enterprise Value EBITDA -12.65
Price Book MRQ 220.85

Technical Indicators RYTM

For 52 Weeks

40.61 USD 69.89 USD
50 Day MA 62.81 USD
Shares Short Prior Month 4 775 505
200 Day MA 57.16 USD
Short Ratio 8.22
Shares Short 4 757 385
Short Percent 9.71 %